The U.S. Food and Drug Administration (FDA) granted a supplemental approval for Opdivo (nivolumab) on March 5, 2018. This approval, designated as an efficacy supplement, expands the approved uses of the immunotherapy drug.
Background
Nivolumab, marketed as Opdivo, is an established immunotherapy drug developed by Bristol Myers Squibb. As an existing approved therapy, supplemental applications allow for the expansion of its label to include new indications, patient populations, or dosing regimens, based on new clinical data demonstrating efficacy. This specific supplemental approval focused on demonstrating additional efficacy for the drug.
What this means
A supplemental approval for efficacy signifies that new clinical data has been reviewed and accepted by the FDA, supporting an expansion of Opdivo's approved therapeutic applications. While the specific details of the expanded indication or patient population are not provided in this summary, such approvals typically mean that the drug has demonstrated a significant benefit in a new context. This could involve treating a different type of cancer, a different stage of an existing indication, or a new line of therapy. For clinicians, researchers, and patient advocates, this type of approval broadens the available treatment options and reinforces the drug's therapeutic value. It indicates that further evidence has solidified nivolumab's role in disease management, potentially offering new hope for patients in previously underserved areas or providing more effective strategies for existing conditions.
Source
Information regarding this supplemental approval was obtained from the U.S. Food and Drug Administration (FDA). The approval for BLA 125554 S-61, concerning a supplemental application for Opdivo (nivolumab) for efficacy, was dated March 5, 2018, and is publicly accessible on accessdata.fda.gov.